
Moderna, SELLAS Life Sciences Group, and AbbVie are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that develop or commercialize products and technologies in areas such as medicines, vaccines, diagnostics, and genetic research. Their prices can be especially volatile because company prospects often depend on clinical-trial results, regulatory decisions, and the ability to fund and bring products to market. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of NASDAQ:MRNA traded down $3.18 during trading on Wednesday, hitting $203.62. The company’s stock had a trading volume of 2,718,546 shares, compared to its average volume of 12,484,358. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $280.80. The business has a 50 day moving average price of $204.39 and a two-hundred day moving average price of $98.06. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. The company has a market capitalization of $82.39 billion, a PE ratio of -28.45 and a beta of 1.16.
Read Our Latest Research Report on MRNA
SELLAS Life Sciences Group (SLS)
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
NASDAQ:SLS traded up $0.92 during trading hours on Wednesday, reaching $20.07. 19,525,542 shares of the company’s stock were exchanged, compared to its average volume of 8,404,106. The company has a 50-day moving average of $11.01 and a 200 day moving average of $8.87. SELLAS Life Sciences Group has a 1-year low of $1.39 and a 1-year high of $24.89. The firm has a market capitalization of $4.09 billion, a price-to-earnings ratio of -102.69 and a beta of 2.73.
Read Our Latest Research Report on SLS
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE:ABBV traded down $3.38 during trading hours on Wednesday, hitting $289.44. The company’s stock had a trading volume of 1,332,570 shares, compared to its average volume of 6,261,019. The company has a market capitalization of $511.62 billion, a PE ratio of 49.73, a PEG ratio of 1.34 and a beta of 0.20. AbbVie has a 52-week low of $190.75 and a 52-week high of $302.93. The business’s 50-day moving average is $277.14 and its two-hundred day moving average is $241.64.
Read Our Latest Research Report on ABBV
See Also
- MarketBeat’s Top Five Stocks to Own in November 2026
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
